Physician profile
Michael Irwin Boone
NPI 1467494203
$24,858.32
in general payments reported to CMS, 2019-2025
20 companies · $9,340 in 2025
The $9,340 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,416 · 2020: $497 · 2021: $2,230 · 2022: $6,573 · 2023: $3,896 · 2024: $907 · 2025: $9,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,125 · Food and Beverage: $3,879 · Travel and Lodging: $2,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,125.00 |
| Food and Beverage | $3,878.67 |
| Travel and Lodging | $2,138.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $14,467.64 | 2019-2025 | Argos, Clareon, Lensx |
| Glaukos Corporation | $8,676.80 | 2019-2025 | Travoprost Intraocular Implant - Idose, Idosetr, Kxl System (Not Refurbished) |
| Alcon Research LLC | $350.00 | 2023 | |
| Sight Sciences, INC. | $205.64 | 2022-2024 | Omni Surgical System |
| Rxsight INC | $162.77 | 2023-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $144.21 | 2024-2025 | Miebo, Vyzulta, Xiidra |
| Aerie Pharmaceuticals, INC. | $141.49 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $130.86 | 2019-2021 | |
| Omeros Corporation | $121.97 | 2019-2021 | |
| Amgen INC. | $67.71 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $57.11 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $53.04 | 2025 | Acthar |
| Rayner Intraocular Lenses Limited | $48.66 | 2022-2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Oyster Point Pharma, INC. | $47.56 | 2023-2024 | Tyrvaya |
| Carl Zeiss Meditec Ag | $38.80 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $38.14 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $34.04 | 2024 | Xdemvy |
| Carl Zeiss Meditec, INC. | $31.60 | 2019 | |
| Allergan, INC. | $24.50 | 2021 | |
| Abbvie INC. | $15.78 | 2023 | Durysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Boone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.